Gilead has partnered with Global Fund to supply lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP).

The Joint United Nations Programme on HIV/AIDS (UNAIDS) warns that the global AIDS response is in crisis after a major funding collapse at the start of 2025 threatens to reverse decades of progress.

HIV jab has signed a deal to supply the costly injection at a knock-down price to as many as two million people in poorer countries.

The first lenacapavir jabs will be delivered later this year under a new agreement between Gilead Sciences and the Global Fund ...

Note that some links may require registration or subscription. The Department of Justice said it sent more than 20 subpoenas to doctors and clinics involved with transgender medical procedures on ...

UN officials warned that if the funding is not replaced, the world will see more than 4 million AIDS-related deaths and another 6 million HIV infections by 2029 ...

Through a strategic, non-profit agreement, Gilead will supply up to two million doses of the long-acting HIV prevention drug ...

National Treasury has allocated R753 million to the Department of Health -- under Section 16 of the Public Finance Management ...

While the National Treasury has released R700m, the Bill and Melinda Gates Foundation and the Wellcome Trust will ...

We also do home visits to make sure that the mothers take their medication on time, and to look after their babies when they ...

UNAIDS today launched its 2025 Global AIDS Update, AIDS, Crisis and the Power to Transform , which shows that a historic funding crisis is ...

South Africa will be among the first countries in the world to receive doses of lenacapavir, the long-acting HIV prevention drug administered once every six months. This was announced by health ...